Your session is about to expire
← Back to Search
Monoclonal Antibodies
Guselkumab for Crohn's Disease (FUZION CD Trial)
Phase 3
Recruiting
Research Sponsored by Janssen-Cilag Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Has at least one active draining perianal fistula as a complication of Crohn's disease, confirmed by screening magnetic resonance imaging (MRI) results
Must have a diagnosis of Crohn's disease with a minimum duration of at least 3 months
Must not have
History of or concurrent rectovaginal fistulas, rectal and/or anal stenosis or other active complications of perianal disease
Has a history of ongoing, chronic or recurrent enteral or systemic infectious disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to week 48 and week 96
Awards & highlights
Pivotal Trial
Summary
This trial tests a medicine called guselkumab on adults with severe Crohn's disease who haven't responded to other treatments. The study will last over two years and will check both how well the medicine works and its safety. Guselkumab is already approved for treating other conditions like plaque psoriasis and psoriatic arthritis.
Who is the study for?
This trial is for individuals with Crohn's disease who've had it for at least 3 months and have at least one active draining perianal fistula. They must be new to biologic treatments or not responding well to current therapies. People with severe luminal disease, rectovaginal fistulas, ongoing infections, or complications that could need surgery can't join.
What is being tested?
The study is testing the effectiveness of a drug called Guselkumab in treating fistulizing, perianal Crohn's disease compared to a placebo. It aims to see if this medication can help manage symptoms better than no treatment.
What are the potential side effects?
While the specific side effects are not listed here, Guselkumab may cause immune system reactions since it targets certain proteins involved in inflammation which could lead to infection risks and other potential immune-related issues.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have at least one active draining fistula due to Crohn's disease, confirmed by MRI.
Select...
I have been diagnosed with Crohn's disease for at least 3 months.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have or had complications related to perianal disease.
Select...
I have a long-term or recurring infection.
Select...
I have complications from Crohn's disease that may need surgery.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to week 48 and week 96
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to week 48 and week 96
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Percentage of Participants who Achieve Combined Fistula Remission at Week 24
Secondary study objectives
Change From Baseline in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Score by Visit Over Time Through Week 48
Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Crohn's Disease (WPAI:CD) by Visit Over Time Through Week 48
Change from Baseline in Crohn's Disease Activity Index (CDAI) by Visit Over Time Through Week 48
+35 moreSide effects data
From 2020 Phase 4 trial • 1027 Patients • NCT035733231%
Nasopharyngitis
1%
Upper respiratory tract infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ixekizumab Post-Treatment Follow Up
Ixekizumab
Guselkumab
Guselkumab Post-Treatment Follow Up
Awards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
3Treatment groups
Experimental Treatment
Group I: Group 3: PlaceboExperimental Treatment2 Interventions
Participants will receive placebo IV infusion followed by placebo SC. At Week 24, placebo non-responders will continue to receive guselkumab Dose 4 followed by guselkumab Dose 2 SC. Participants will receive matching placebo to maintain the blind. Participants who are eligible and willing to continue guselkumab may enter the LTE period and continue to receive guselkumab.
Group II: Group 2: GuselkumabExperimental Treatment2 Interventions
Participants will receive guselkumab Dose 1 IV infusion followed by Dose 3 SC. Participants will receive matching placebo to maintain the blind. At Week 24, guselkumab Dose 3 SC non-responders will switch to receive guselkumab dose 2 SC. Participants who are eligible and willing to continue guselkumab may enter the LTE period and continue to receive guselkumab.
Group III: Group 1: GuselkumabExperimental Treatment2 Interventions
Participants will receive guselkumab Dose 1 intravenous (IV) infusion followed by Dose 2 subcutaneously (SC). Participants will receive matching placebo to maintain the blind. Participants who are eligible and willing to continue guselkumab may enter the Long-Term Extension (LTE) period and continue to receive guselkumab.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Guselkumab
2015
Completed Phase 4
~6080
Placebo
1995
Completed Phase 3
~2670
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Crohn's Disease include biologic therapies such as anti-TNF agents (e.g., infliximab, adalimumab), which block tumor necrosis factor-alpha (TNF-α), a cytokine involved in systemic inflammation. Another class includes IL-23 inhibitors like Guselkumab, which target the interleukin-23 pathway, crucial in the inflammatory process of Crohn's Disease.
Immunomodulators (e.g., azathioprine) suppress the immune response more broadly. These treatments are essential as they help reduce inflammation, manage symptoms, and induce and maintain remission, improving the quality of life for patients with Crohn's Disease.
Popular exclusionary diets for inflammatory bowel disease: the search for a dietary culprit.
Popular exclusionary diets for inflammatory bowel disease: the search for a dietary culprit.
Find a Location
Who is running the clinical trial?
Janssen-Cilag Ltd.Lead Sponsor
99 Previous Clinical Trials
48,576 Total Patients Enrolled
Janssen-Cilag Ltd. Clinical TrialStudy DirectorJanssen-Cilag Ltd.
18 Previous Clinical Trials
12,653 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have or had complications related to perianal disease.I have a long-term or recurring infection.I have at least one active draining fistula due to Crohn's disease, confirmed by MRI.I have been diagnosed with Crohn's disease for at least 3 months.My bowel condition is very severe.I have complications from Crohn's disease that may need surgery.I have Crohn's Disease and haven't responded well to standard or biologic treatments.
Research Study Groups:
This trial has the following groups:- Group 1: Group 3: Placebo
- Group 2: Group 1: Guselkumab
- Group 3: Group 2: Guselkumab
Awards:
This trial has 1 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.